| Document |
Document Title |
|
WO/2024/093056A1 |
The present invention relates to a T cell receptor (TCR) specifically binding to a KRAS_G12V mutant antigen, a fusion protein or conjugate comprising the TCR, a nucleic acid encoding the TCR and an engineered cell comprising same, and a ...
|
|
WO/2024/097852A1 |
This document relates to methods and materials for using engineered mesenchymal stromal cells (MSCs) to treat a mammal (e.g., a human) in need of immunosuppression (e.g., a human having or at risk of developing one or more autoimmune dis...
|
|
WO/2024/093681A1 |
Provided is use of infigratinib or a pharmaceutically acceptable salt thereof in preparing a medicament for treating and/or preventing gastric cancer or gastroesophageal junction adenocarcinoma, in particular, locally advanced or recurre...
|
|
WO/2024/094685A1 |
The present invention relates to CCR2 inhibitors that are variant CCL2 polypeptides comprising a variant N-terminal portion and a conserved C-terminal portion, and peptides and uses thereof.
|
|
WO/2024/092717A1 |
Provided is a protein derived from a fibronectin type III domain, and the use thereof. The protein comprises the 10th human fibronectin type III domain, and comprises a first mutation where one amino acid site is substituted with one cys...
|
|
WO/2024/097772A1 |
The present application provides compositions for treatment of Friedreich's Ataxia (FA). These include, but are not limited to, nucleic acid constructs and recombinant AAV7 vectors comprising a human frataxin 5' untranslated region (5'UT...
|
|
WO/2024/094690A1 |
Antigen binding proteins of the invention bind to Human Immunodeficiency Virus (HIV) envelope protein and are useful in treating and preventing HIV infection. In particular, the antigen binding proteins bind to two different epitopes on ...
|
|
WO/2024/096121A1 |
The present disclosure provides a bacterial preparation that can be used to treat inflammatory bowel disease. More specifically, the present disclosure relates to a microorganism in which a gene from at least one of a fimbria operon gene...
|
|
WO/2024/098005A1 |
This present invention provides a pharmaceutical composition comprising one or more ACAT inhibitors and one or more GLP-lRAs. It also provides a method for controlling body weight comprising co-administering to a subject in need one or m...
|
|
WO/2024/097051A1 |
The disclosure leverages the therapeutic potential of autologous and allogenic cells, particularly cancer cells and T cells, which have been genetically modified or contacted with specific recombinant proteins, peptides, or nucleic acids...
|
|
WO/2024/093554A1 |
The present invention relates to the field of biomedicine, in particular to a recombinant subunit vaccine against respiratory syncytial virus (RSV) and a use thereof, and more in particular to a recombinant fusion protein containing the ...
|
|
WO/2024/096218A1 |
The present invention relates to a modified microorganism of the genus Corynebacterium producing L-glutamic acid and a method for producing L-glutamic acid using same, more specifically to a novel variant of nicotinamide mononucleotide t...
|
|
WO/2024/095213A1 |
The present disclosure provides nucleic acids, compositions and vectors containing and their use for effecting gene editing and/or gene expression alteration on sickle cell disease (SCD)-associated genes, e.g., in vivo. The present discl...
|
|
WO/2024/097990A1 |
Recombinant yeasts bioengineered to overexpress genes for utilization of cellulosic and hemicellulosic fibers and/or produce lipid, and methods of use thereof. The yeasts are modified to express, constitutively express, or overexpress an...
|
|
WO/2024/093843A1 |
Disclosed are a disease resistance-related protein RCR1, a coding gene thereof, and use thereof. The disease resistance-related protein RCR1 provided by the present invention is a protein set forth in sequence 2. The present invention de...
|
|
WO/2024/094775A1 |
This document relates to engineered immune cells comprising a tumor-CAR and a FAPscFv-cytokine fusion protein with differential expressions, their use in the treatment of tumors expressing FAP, as well as methods and materials for the pr...
|
|
WO/2024/094747A1 |
This application relates to new C-type natriuretic peptide (CNP) compounds, pharmaceutical compositions comprising these compounds, and these compounds for use as medicaments.
|
|
WO/2024/097793A1 |
Provided herein is a method of manufacturing recombinant immune cells that comprise a nucleic acid encoding an engineered immune receptor. In some embodiments, the method comprises incubating the cells in vitro with an mTor inhibitor (e....
|
|
WO/2024/097797A1 |
T cells expressing a chimeric antigen receptor (CAR) targeting CD3 can be susceptible to fratricide because T cells express CD3 on their surface as part of the T cell receptor (TCR)/CD3 complex. To reduce fratricide, CD3 surface expressi...
|
|
WO/2024/096540A1 |
The present invention relates to a method for producing a recombinant SOD3 protein. Compared to SOD3-WT, HBD partial deletion (CKAA deletion) enables the production of SOD3 in the form of a homogeneous tetramer, can increase the expressi...
|
|
WO/2024/094612A1 |
The invention relates to the treatment of a neurodegenerative diseases, via intra-putaminal route of administration, with recombinant adeno-associated viral (rAAV) particles comprising an AAV true type (AAVTT) capsid and a heterologous n...
|
|
WO/2024/094850A1 |
The present invention relates to novel polypeptides, which are derived from transforming growth factor beta 1 (TGFβ1; TGFb-1) as well as polynucleotides encoding such polypeptides and compositions comprising such peptides. The present i...
|
|
WO/2024/097992A2 |
Provided herein are particles comprising a fusion molecule comprising an adhesion molecule linked to a costimulatory molecule or an activation molecule, as well as vectors, such as lentiviral vectors, comprising the same, cells comprisin...
|
|
WO/2024/092346A1 |
The present invention relates to an expression vector that encodes all or a portion of replicon proteins from a positive stranded virus, wherein expression of the replicon proteins is under the control of CMV and T7 promoters, and wherei...
|
|
WO/2024/097875A1 |
The present disclosure relates to, inter alia, compositions and methods, including heterologous chimeric proteins that find use, inter alia, in the treatment of nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NAS...
|
|
WO/2024/095209A1 |
Provided herein are expression vectors, vector production systems, bacterial sequence- free vectors, and methods for producing adeno-associated viruses (AAVs). Also provided are AAVs as well as pharmaceutical compositions and uses thereof.
|
|
WO/2024/097836A1 |
Provided herein are assays and methods for identifying which of a plurality of drugs is responsible for causing a delayed-type drug hypersensitivity reaction (dtDHR) in a patient.
|
|
WO/2024/097979A1 |
Disclosed are nucleic acids encoding a chimeric antigen receptor comprising an extracellular domain comprising an antigen recognition domain consisting of a fully human single variable heavy (VH) domain that binds a first epitope on B-ce...
|
|
WO/2024/089551A1 |
The present disclosure provides MSLN binding agents in the monospecific and multispecific formats, including bispecific MSLN x CD3 binding proteins, and related compositions and methods of use.
|
|
WO/2024/092026A1 |
Provided herein are methods and compositions for treating a subject having an B cell- associated autoimmune disease, such as lupus nephritis, using T cells engineered with a chimeric antigen receptor that binds CD 19.
|
|
WO/2024/091701A1 |
Provided herein are compositions and methods for tissue repair. In particular, the compositions and methods described herein find use in repairing, regenerating, and modulating fibrosis and inflammation in a variety of tissues such as, f...
|
|
WO/2024/089131A1 |
The present invention is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The present invention provides a cell for the production of one or more bioproduct(s) wherein the cell is capable to produc...
|
|
WO/2024/089270A2 |
The present invention relates to novel pore monomers, pores formed from the pore monomers and their uses in analyte detection and characterisation.
|
|
WO/2024/091959A1 |
Compositions and method of prevention and treatment for a subject in need comprising drug-resistant natural killer (NK) cells, which are effective for treating cancer when administered in conjunction with cytotoxic therapies. A method of...
|
|
WO/2024/090998A1 |
The present invention relates to a YaxAB nanopore, a system comprising the nanopore and applications thereof. The YaxAB nanopore of the present invention has a funnel-shaped three-dimensional structure so that a change in current blockin...
|
|
WO/2024/087336A1 |
Disclosed in the present invention are an all-genetically encoded NMN protein probe based on resonance energy transfer, and a use thereof, and particularly, an all-genetically encoded NMN protein probe, which is formed by connecting a re...
|
|
WO/2024/091848A2 |
The present disclosure provides modified immune cells or precursors thereof (e.g., gene edited modified T cells) comprising chimeric antigen receptors (CARs) specific for CEACAM6
|
|
WO/2024/091921A1 |
Disclosed are stabilized type I fusion proteins (e.g., HIV envelope proteins). For HIV-1, the stabilization of Env due to the disclosed modications are compatible and, in some embodiments, synergistic with stabilization mutations known a...
|
|
WO/2024/092131A1 |
The present disclosure relates to engineered gastrointestinal bacteria expressing IL-22 and/or IFN-β and uses thereof for treatment of cancer.
|
|
WO/2024/090893A1 |
The present invention relates to extracellular vesicles (EVs) overexpressing fibronectin fragment protein, and a use for drug delivery thereof. The present invention relates to a method for increasing EV delivery efficiency into cells by...
|
|
WO/2024/091589A1 |
An immunogen generally includes an immunogenic carrier that includes a virus-like particle (VLP) and an antigenic Anopheles spp. TRIO peptide that includes amino acids VDDLMAKFN (SEQ ID NO:1) or AANLRDKFN (SEQ ID NO:5) linked to the immu...
|
|
WO/2024/089297A1 |
Disclosed are methods to obtain enhanced variants of fluorescent and bioluminescent proteins based on ratiometric measurement of luminescence. Disclosed are furthermore engineered variants of a yellow fluorescent protein (YFP) derived fr...
|
|
WO/2024/091540A1 |
The present disclosure relates to compositions and methods for the suppression of silencing of a gene of interest in plants. Also disclosed are vectors, transgenic plants and plant parts comprising genetic constructs for suppressing endo...
|
|
WO/2024/091694A1 |
A chimeric protein encoded by an expression plasmid is provided. The chimeric protein comprises an extracellular of a pathogen-binding receptor and an intracellular domain of an innate immune signaling protein, such as the TLR family of ...
|
|
WO/2024/091902A1 |
The disclosure provides, in various embodiments, non-human animals that comprise a human immune cell engraftment and/or functional human immune system. The disclosure also provides, in various embodiments, methods of generating said non-...
|
|
WO/2024/092058A1 |
The invention is directed to modified HIV-1 envelopes, compositions comprising these modified envelopes, nucleic acids encoding these modified envelopes, compositions comprising these nucleic acids, and methods of using these modified HI...
|
|
WO/2024/089248A1 |
The present invention relates to a recombinant activation-associated secreted protein (ASP) or fragment thereof, said ASP or fragment comprising an N-glycan comprising a core α1,3-fucose and/or a core α1,6-fucose (Fuc). The invention f...
|
|
WO/2024/087429A1 |
Use of an antibody for detecting a protein biomarker group in the preparation of a kit for diagnosing Alzheimer's disease (AD), mild cognitive impairment (MCI) and other types of senile dementia. The protein biomarker group comprises a p...
|
|
WO/2024/090884A1 |
The present invention relates to a novel phenylalanine:H+ symporter PheP variant and a method for producing L-aromatic amino acids using same, wherein the protein activity of the phenylalanine:H+ symporter PheP variant changes as at leas...
|
|
WO/2024/091909A1 |
Described are methods of inducing a protective immune response against Lassa virus comprising administering a prophylactically effective amount of a nucleic acid molecule encoding a Lassa virus glycoprotein precursor (LASV GPC) to a subj...
|
